StonvexLoading…
StonvexStonvexStonvexCore line items from DTM's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $336.00M | $1.24B | $926.00M | $612.00M |
Operating Income | $166.00M | $614.00M | $458.00M | $303.00M |
Net Income | $130.00M | $441.00M | $330.00M | $215.00M |
EPS (Diluted) | $1.27 | $4.30 | $3.22 | $2.10 |
Total Assets | $10.15B | $10.08B | $10.06B | $9.96B |
Total Liabilities | $5.26B | $5.20B | $5.22B | $5.14B |
Cash & Equivalents | $150.00M | $54.00M | $98.00M | $74.00M |
Free Cash Flow OCF − CapEx | $202.00M | $441.00M | $411.00M | $280.00M |
Shares Outstanding | 102.01M | 101.67M | 101.67M | 101.59M |